AVN-944

DCTPepD ID  DCTPepD0062

Active Ingredients   AVN-944

Description  An orally available, synthetic small molecule with potential antineoplastic activity. AVN944 inhibits inosine monosphosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanosine triphosphate (GTP), a purine molecule required for DNA and RNA synthesis. Inhibition of IMPDH deprives cancer cells of GTP, resulting in disruption of DNA and RNA synthesis, inhibition of cell proliferation, and the induction of apoptosis. AVN944 appears to have a selective effect on cancer cells in that deprivation of GTP in normal cells results in a temporary slowing of cell growth only. IMPDH is overexpressed in some cancer cells, particularly in hematological malignancies.

Synonyms  AVN944; AVN 944; Inosine Monophosphate Dehydrogenase Inhibitor AVN944; AVN-944

Disease  Leukemia, Lymphoma, Multiple myeloma, Pancreatic cancer

Classification

  

IMPDH inhibitor Peptide and derivative

Structure Information


Molecular Formula  C25H27N5O5

Molecular Weight  477.5

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  [(2R)-1-cyanobutan-2-yl] N-[(1S)-1-[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]ethyl]carbamate

InChI  InChI=1S/C25H27N5O5/c1-4-20(10-11-26)35-25(32)28-16(2)17-6-5-7-18(12-17)29-24(31)30-19-8-9-21(22(13-19)33-3)23-14-27-15-34-23/h5-9,12-16,20H,4,10H2,1-3H3,(H,28,32)(H2,29,30,31)/t16-,20+/m0/s1

InChI_Key GYCPCOJTCINIFZ-OXJNMPFZSA-N

SMILES  CC[C@@H](OC(N[C@H](C1=CC=CC(NC(NC2=CC(OC)=C(C=C2)C3=CN=CO3)=O)=C1)C)=O)CC#N

External Codes


PubChem CID  9918559

DrugBank Accession Number  DB05500

NCI Thesaurus Code  C49181  

UNII  I3NPL1V48Q   GSRS

CAS  297730-17-7



Drug approval


Drug indication
    Investigated for use/treatment in cancer/tumors (unspecified), leukemia (unspecified), lymphoma (unspecified), multiple myeloma, and pancreatic cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00273936 A Phase I Trial of AVN-944 in Patients With Advanced Hematologic Malignancies Acute Leukemia; Chronic Leukemia; Multiple Myeloma; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Waldenstrom's Macroglobulinemia Phase 1 Treatment
NCT00923728 A Phase 1 Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors Refractory Solid Tumors Not Applicable Treatment
NCT00493441 A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer Pancreatic Cancer Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.